科研成果：科学论文与知识产权

专注给予质高价优

的生物药

科学论文

Serplulimab vs. placebo combined with chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Extended follow-up results and patient-reported outcomes from the international phase 3 ASTRUM-005 study
ASCO 2024
Exploratory biomarker analysis of phase 3 ASTRUM-005 study: Serplulimab versus placebo plus chemotherapy for extensive-stage small cell lung cancer
AACR 2024
Real-world first-line serplulimab-based immunochemotherapy for extensive-stage small cell lung cancer: The Multicenter ASTRUM-005R study
ASCO 2024
Neoadjuvant chemoimmunotherapy in patients with limited-stage small cell lung cancer: A retrospective study
ASCO 2024
Induction therapy with PD-1 antibody combined with platinum-based doublet chemotherapy for locally-advanced non-small cell lung cancer: A randomised controlled, open-label, phase 2 trial
ASCO 2024
Neoadjuvant serplulimab in combination with concurrent chemoradiotherapy for locally advanced, resectable esophagogastric junction adenocarcinoma
ASCO 2024

知识产权

专利申请数量	PCT申请数量	国内外授权专利数量	注册司法权区	申请日期	到期日	发明专利数量
809	90	134	中国大陆	2011-03-18	2031-03-18	97

OB视讯(中国)